Sarcoma

1 stories · following the connections

Business

New Randomized Data From CMB305 + Checkpoint Inhibitor Study Demonstrate Greater Clinical Benefit and Immune Response

By Nasdaq OMXSep 8, 2017, 8:00 AM UTC